Omontys Injection Now Available
Affymax Inc. and Takeda announced that Omontys (peginesatide) Injection is now available for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Omontys is a new synthetic, PEGylated peptidic compound that stimulates the bone marrow to produce more red blood cells to reduce the need for transfusions in patients with CKD.
Omontys injection is available in single use vials (2mg/0.5mL, 3mg/0.5mL, 4mg/0.5mL, 5mg/0.5mL, 6mg/0.5mL), single use pre-filled syringes (1mg/0.5mL, 2mg/0.5mL, 3mg/0.5mL, 4mg/0.5mL, 5mg/0.5mL, 6mg/0.5mL), and multiple use vials (10mg/mL, 20mg/mL).
For more information call (855) 466-6689 or visit www.omontys.com.